Matt enables late R&D and early commercial teams for new oncology medicines, pursuing emerging targets through new modalities.

Matt is an associate partner who works in the ZS Philadelphia office, leading the Radiopharmaceutical Center of Excellence. With more than 10 years at ZS, he drives oncology strategies across portfolio planning, commercial strategy, market research, forecasting and data analytics.

Matt is a strategic adviser in the development and commercialization of novel oncology therapeutics. He has expertise in solid tumors and hematological malignancies, and specializes in the intersection of therapeutic targets, modalities and tumor types. Matt’s experience with targeted radiopharmaceuticals, cell therapies, antibody drug conjugates and multi-specific antibodies make him a published thought leader in oncology topics. Over the past 10 years, Matt has attended various oncology medical congresses on behalf of ZS. 

Before ZS, Matt worked with a healthcare consulting firm focused primarily on cardiovascular and oncology spaces. Prior to consulting, he studied the impact of diet on the biophysics of neutrophil cell membranes.

Matt holds a Ph.D. in bioengineering from the University of Pennsylvania. He also holds a BSE in Biomedical Engineering from Duke University.